07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Genfit, OSEO endocrine news

Genfit will receive €7.1 million ($11.2 million) in funding over five years from OSEO as part of the Therapeutic Innovation (IT-Diab) program to develop diagnostics and therapeutics for pre-diabetic conditions. Genfit will lead a consortium...
07:00 , Jun 28, 2004 |  BioCentury  |  Politics, Policy & Law

What's in a model?

Drug development relies heavily on animal models to validate targets, to anticipate the effect of a drug on a target of interest, and to assess potential side effects. Yet despite the fact that creating good...
08:00 , Dec 16, 2002 |  BioCentury  |  Politics, Policy & Law

U.K.'s boost to cancer trials

The U.K.'s National Health Service plans to support a plan by the National Translational Cancer Research Network (NTRAC) to improve coordination of early stage clinical trials in cancer. NHS has allocated a budget of £10...
07:00 , May 20, 2002 |  BC Week In Review  |  Company News

Genome express SA other research news

Genome express received a E1 million ($914,000) grant from ANVAR, the French Agency for Innovation, to develop services to explore and sequence bacterial genomes for the healthcare, agri-food and environmental sectors. Genome express SA ,...
08:00 , Mar 25, 2002 |  BC Week In Review  |  Company News

EntoMed other research news

Entomed received a E1.5 million ($1.3 million) interest-free loan from French agency ANVAR to industrialize production of ETD-151 to treat hospital-acquired fungus infections and for pre-clinical studies of the compound. ETD-151 was derived from an...
08:00 , Jan 28, 2002 |  BioCentury  |  Emerging Company Profile

Innate: Teaching the immune system

Very few methods have succeeded in manipulating the human immune system to handle new diseases on its own. Innate Pharma SAS has developed a new class of small molecules that stimulate specific subsets of so-called...
08:00 , Jan 28, 2002 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Innate Pharma SAS Marseille, France Technology: Immunology Disease focus: Cancer, adjuvants, infectious disease, autoimmune Clinical status: Phase I to start in 2002 Founded: 1999 by Hervé Brailly, Francois Romagné, Marc Bonneville, Jean-Jacques Fournié, Eric Vivier,...
07:00 , Jul 6, 1998 |  BC Week In Review  |  Company News

ExonHit Therapeutics SA other research news

ExonHit, a gene profiling company, will receive FF5 million (US$830,000) from the French government's ANVAR innovation agency to expand its R&D program for its DATAS (differential analysis of transcripts alternatively spliced) technology. ExonHit Therapeutics SA...
08:00 , Mar 23, 1998 |  BioCentury  |  Politics, Policy & Law

GMOs edge forward

AgrEvo, Monsanto and Novartis have moved closer to being able to commercialize a number of genetically modified seeds in Europe. Members of the regulatory committee overseeing Directive 90/220/EEC, the so-called deliberate release into the environment...
07:00 , Sep 2, 1997 |  BioCentury  |  Strategy

Back to School: Nightmares, etc.

BioCentury frequently is asked whether we ever run out of topics to write about. The truth of the matter is that as the industry has grown, the number of subjects to cover has grown with...